rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Roger Sawhney

Director

Company insider

Files Form 4 as: Director, Arbutus Biopharma; Director, Actuate Therapeutics; Director, Alimera Sciences; Chief Financial Officer, Omega Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
21
Buys
1
Sells
0
Bought
$50K
Sold
$0
Companies
4
Companies where not an officer
3
First trade
3 Aug 2021
Last trade
1 Oct 2026
Last filed
7 Oct 2026

Companies traded

Where they are an officer
Omega TherapeuticsOfficer · last 9 Mar 20221 buy · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
ABUS Arbutus BiopharmaDirector · Biotechnology · last 1 Oct 20260 buys · 0 sells
ACTU Actuate TherapeuticsDirector · Biotechnology · last 21 May 20260 buys · 0 sells
Alimera SciencesDirector · last 25 Feb 20230 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 7 Oct 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code D$86K17,142 at $5.00filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code M$175K52,533 at $3.34filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code M$334K78,800 at $4.24filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code F$510K100,508 at $5.07filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code M—52,533 at $0.00filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code M—78,800 at $0.00filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code M—52,533 at $0.00filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code M—78,800 at $0.00filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code M$175K52,533 at $3.34filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code M$334K78,800 at $4.24filing
18 Sep 2026filed 23 Sep 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code F$510K100,508 at $5.07filing
8 Jun 2026filed 10 Jun 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—78,800 at $0.00filing
8 Jun 2026filed 10 Jun 2026ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—78,800 at $0.00filing
21 May 2026filed 22 May 2026ACTU Actuate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
21 May 2026filed 22 May 2026ACTU Actuate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
4 Aug 2025filed 6 Aug 2025ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—157,600 at $0.00filing
22 May 2025filed 23 May 2025ACTU Actuate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
12 Aug 2024filed 14 Aug 2024ACTU Actuate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
25 Feb 2023filed 1 Mar 2023Alimera Sciencesoption or derivativeSEC FORM 4 Code A—2,252 at $0.00filing
9 Mar 2022filed 11 Mar 2022Omega Therapeuticsoption or derivativeSEC FORM 4 Code A—60,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.